Conmed expands portfolio with Bard's endoscopic line
This article was originally published in Clinica
Executive Summary
Conmed is to acquire from CR Bard certain products from its Endoscopic Technologies business, including its line of single-use medical devices used to diagnose and treat diseases of the digestive tract and lungs. The transaction will cost Conmed $80m in total, of which $30m will be an up-front cash payment and the rest in borrowings under its revolving line of credit.